Article
Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging.
Scientific reports - 23 Mar 2023
Watanabe Fumiaki, Suzuki Koichi, Aizawa Hidetoshi, Endo Yuhei, Takayama Yuji, Kakizawa Nao, Kato Takaharu, Noda Hiroshi, Rikiyama Toshiki
Abstract excerpt
Molecular assessment using circulating tumor DNA (ctDNA) has not been well-defined. We recruited 61 pancreatic cancer (PC) patients who underwent initial computed tomography (CT) imaging study during first-line chemotherapy. Initial molecular assessment was performed using droplet digital PCR and defined as the change in KRAS-mutated ctDNA before and after treatments, which was classified into five categories:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.